Wall Street analysts expect Tricida Inc (NASDAQ:TCDA) to report earnings per share of ($0.89) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Tricida’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.83). Tricida reported earnings per share of ($0.66) in the same quarter last year, which would suggest a negative year over year growth rate of 34.8%. The firm is expected to report its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Tricida will report full year earnings of ($3.53) per share for the current financial year, with EPS estimates ranging from ($3.65) to ($3.40). For the next financial year, analysts anticipate that the company will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.10) to ($3.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Tricida.
Tricida (NASDAQ:TCDA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.12.
TCDA stock traded down $0.24 during mid-day trading on Tuesday, reaching $35.96. 231,281 shares of the stock traded hands, compared to its average volume of 267,361. The company has a quick ratio of 14.22, a current ratio of 14.23 and a debt-to-equity ratio of 0.11. Tricida has a 52 week low of $19.43 and a 52 week high of $42.80. The business has a 50-day moving average of $32.89 and a two-hundred day moving average of $34.08. The firm has a market capitalization of $1.82 billion, a PE ratio of -7.75 and a beta of 0.79.
In other news, Director Robert J. Alpern sold 1,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $31.60, for a total transaction of $31,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Geoffrey M. Parker purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were bought at an average cost of $32.33 per share, for a total transaction of $969,900.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 75,755 shares of company stock valued at $2,425,608. Company insiders own 66.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Tricida by 23.4% in the second quarter. BlackRock Inc. now owns 2,356,417 shares of the company’s stock valued at $92,984,000 after acquiring an additional 447,562 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Tricida by 54.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 145,215 shares of the company’s stock valued at $5,731,000 after acquiring an additional 51,076 shares during the last quarter. MetLife Investment Advisors LLC boosted its stake in Tricida by 68.8% in the first quarter. MetLife Investment Advisors LLC now owns 8,804 shares of the company’s stock valued at $340,000 after acquiring an additional 3,587 shares during the last quarter. Artal Group S.A. boosted its stake in Tricida by 60.0% in the second quarter. Artal Group S.A. now owns 360,000 shares of the company’s stock valued at $14,206,000 after acquiring an additional 135,000 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Tricida in the first quarter valued at approximately $2,546,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Recommended Story: Initial Coin Offerings entail a high degree of risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.